Radiopharm Theranostics LTD (RADX) 13F Positioning & Ownership Changes (Q2 2026)

RADX ranks #10936 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

7 institutions disclose a position in RADX, but none treat it as a major bet — even Stonepine Capital Management, LLC, its most concentrated holder, allocates just 0.4% of its own portfolio to it.

Rhumbline Advisers has added to its RADX position for two straight quarters, increasing it by $786.0 to reach $817.0 today.

Hsbc Holdings PLC has trimmed its RADX position for two straight quarters, cutting it by $753.3K while still holding $253.7K.

RADX reported a net loss of $38.3M in its latest fiscal year.

• Not yet profitable — net loss of $38.3M in the latest fiscal year
• Revenue grew 1114.3% year over year
• Net income improved year over year, from -$47.9M to -$38.3M
• Operating cash flow was negative, using $36.6M in cash
• Current ratio of 2.67x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.02x equity — within a conventional range